HK Stock MarketDetailed Quotes

HUTCHMED (00013)

Watchlist
  • 20.060
  • +0.870+4.53%
15min DelayMarket Closed Aug 17 16:05 CST
17.50BMarket Cap124.60P/E (TTM)

About HUTCHMED Company

Hutchison China MediTech is an innovative biopharmaceutical company in the commercialization stage, aiming to become a global leader in the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immune-mediated diseases. We are one of the first innovative pharmaceutical R&D companies in China to focus on the global market. Over the past 20 years, we have built a fully integrated R&D innovation platform with world-class discovery and development capabilities. As of 2020, we have an R&D team of more than 600 professionals and 10 innovative anticancer drugs in clinical stages, currently undergoing clinical trials worldwide. We have also established a deep and profitable commercial platform in the Chinese market, manufacturing, marketing, and distributing prescription drugs and consumer health products in China, including our two innovative oncology drugs—Elunate (fruquintinib capsules) and Sutent (sorafenib capsules)—which are already approved and available in China. Furthermore, we plan to expand our commercial footprint into the United States and Europe. Hutchison China MediTech is listed on the Nasdaq Global Select Market and the London Stock Exchange's Alternative Investment Market (Nasdaq/LSE: HCM).

Company Profile

Symbol00013
Company NameHutchmed (China) co.,Ltd.
ISINKYG4672N1198
Listing DateJun 30, 2021
Issue Price40.10
Shares Offered104.00M share(s)
FoundedDec 18, 2000
Registered AddressCayman Islands
Chairmanlede ai
Secretaryxide shi
Audit InstitutionPwC, PwC Zhongtian Certified Public Accountants (Special General Partnership)
Company CategoryOther
Registered OfficeP.O. Box 309, Ugland House Grand Cayman, KY1-1104 Cayman Islands
Head Office and Principal Place of Business

48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong

Fiscal Year Ends12-31
Employees1790
MarketHong Kong motherboard
Phone(852)21281188;(852)21218200
Fax(852)21281778;(852)21218281
Emailinfo@hutch-med.com;ediths@ckh.com.hk
Websitehttps://www.hutch-med.com
Business

HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

Company Executives

  • Name
  • Position
  • Salary
  • lede ai
  • Chairman, Non-executive Director, Nomination Committee Member, Technical Committee Members
  • 143.00K
  • weiguo su
  • Chief Executive Officer, Executive Director, Chief Scientific Officer, Technical Committee Members
  • 5.42M
  • zefeng zheng
  • Executive Director, Acting Chief Executive Officer, Chief Financial Officer, Member of the Sustainable Development Committee
  • 1.56M
  • xide shi
  • Non-executive Director, Chair of the Sustainable Development Committee, Members of the Remuneration Committee, Authorized Representative, Company Secretary
  • 13.00K
  • ling yang
  • Non-executive Director
  • --
  • siya yan
  • Independent Non-Executive Director, Chair of the Nominating Committee, Chair of the Remuneration Committee, Audit Committee Member, Technical Committee Members
  • 105.00K
  • chaohong hu
  • Independent Non-Executive Director, Chair of the Technical Committee, Audit Committee Member, Nomination Committee Member
  • 99.00K
  • shaowen chen
  • Independent Non-Executive Director, Member of the Sustainable Development Committee, Technical Committee Members
  • 18.00K
  • dewei huang
  • Independent Non-Executive Director, Chairman of the Audit Committee, Members of the Remuneration Committee
  • 83.00K
  • zhenjie zhao
  • Deputy Chief Financial Officer
  • --
  • shixin li
  • Group Legal Director
  • --
Market Insights
Petroleum
No. Symbol 20D % Chg
Sample Name
Sample Code
 +1.82%
Sample Name
Sample Code
 +1.14%
Sample Name
Sample Code
 +0.08%
4
SINOPEC CORP
00386
0.00%
5
SINO OIL & GAS
00702
0.00%
View More
No. Symbol 20D % Chg
Sample Name
Sample Code
 +61.30%
Sample Name
Sample Code
 +21.47%
Sample Name
Sample Code
 +18.72%
4
Hand Enterprise Solutions
300170
+18.49%
5
Capitalonline Data Service
300846
+14.72%
View More
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

- No more -